Learn more about the transformation of psychedelics into medicines

Endpoints News - Being able to combine our digital health capabilities with the new insights into the biological mechanisms, giving rise to antidepressant-like effects will enhance our ability to identify why some patients may respond better to psilocybin or LSD versus ketamine.…

Bloomberg…

Fierce Biotech - Eleusis was founded in 2014 with the mission of turning psychedelics into anti-inflammatories, and now it has data from preclinical study that it will use to guide the development of its first drug candidates to treat inflammatory conditions.…

Lucid News - A long time researcher of psychedelic substances is on the forefront of investigating how these materials may be used to reduce inflammation and support the immune system. These investigations may provide new opportunities for scientists to develop more effective treatments for diseases impacted by inflammation such as Alzheimer’s disease and cancer.…

Lucid News - Taking its name from the Eleusinian Mysteries, the secret religious rites of ancient Greece, Eleusis has raised $14.5 million in two rounds of funding.…

Endpoints News - Being able to combine our digital health capabilities with the new insights into the biological mechanisms, giving rise to antidepressant-like effects will enhance our ability to identify why some patients may respond better to psilocybin or LSD versus ketamine.…